These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 30573519)

  • 1. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
    Phallen J; Leal A; Woodward BD; Forde PM; Naidoo J; Marrone KA; Brahmer JR; Fiksel J; Medina JE; Cristiano S; Palsgrove DN; Gocke CD; Bruhm DC; Keshavarzian P; Adleff V; Weihe E; Anagnostou V; Scharpf RB; Velculescu VE; Husain H
    Cancer Res; 2019 Mar; 79(6):1204-1213. PubMed ID: 30573519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Forde PM; White JR; Niknafs N; Hruban C; Naidoo J; Marrone K; Sivakumar IKA; Bruhm DC; Rosner S; Phallen J; Leal A; Adleff V; Smith KN; Cottrell TR; Rhymee L; Palsgrove DN; Hann CL; Levy B; Feliciano J; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Isbell JM; Sauter JL; Taube J; Scharpf RB; Karchin R; Pardoll DM; Chaft JE; Hellmann MD; Brahmer JR; Velculescu VE
    Cancer Res; 2019 Mar; 79(6):1214-1225. PubMed ID: 30541742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.
    Chiou CC; Wang CL; Luo JD; Liu CY; Ko HW; Yang CT
    Cancer Genomics Proteomics; 2020; 17(4):417-423. PubMed ID: 32576586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
    Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
    Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.
    Yeung KT; More S; Woodward B; Velculescu V; Husain H
    Mol Diagn Ther; 2017 Aug; 21(4):375-384. PubMed ID: 28337711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
    Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.
    Remon J; Isla D; Garrido P; de Castro J; Majem M; Viñolas N; Artal A; Carcereny E; García-Campelo MR; Lianes P; Provencio M; Juan O; Diz P; Blanco R; Lopez-Castro R; Maestu I; Vadell C; Felip E
    Clin Transl Oncol; 2017 Dec; 19(12):1537-1542. PubMed ID: 28660482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour DNA in
    Cabanero M; Tsao MS
    Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.
    Wei Z; Wang W; Shu Z; Zhou X; Zhang Y
    Med Sci Monit; 2017 Jul; 23():3627-3634. PubMed ID: 28742791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
    Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
    Diao Z; Han Y; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer.
    Dai LJ; Wang C; Ding ZY
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1761-1766. PubMed ID: 30049184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.